AI Article Synopsis
- * In the JCOG0502 trial, 368 patients were observed, where 209 opted for surgery and 159 chose CRT, despite having similar characteristics apart from age.
- * A study found that patients aged 65 and older, males, those with multiple lesions, those without children, and the advice of their doctor were key factors in choosing CRT, with the doctor's opinion being the most impactful.
Article Abstract
Treatment options for esophageal squamous cell carcinoma includes surgery and chemoradiotherapy (CRT), however there was limited information about the factors influenced in patients' decision-making. Patients who participated in JCOG0502, a parallel group controlled trial comparing surgery with CRT, were analyzed for the factors related to decision-making. Of the 368 patients (pts) enrolled in the nonrandomized part in JCOG0502, 209 pts opted for surgery and 159 pts chose CRT on their own. Background characteristics were the same except for age. Multivariable logistic regression analysis showed that age ≥65 years, male sex, multiple lesions, absence of children and doctor's thinking were associated with the selection of CRT. The doctor's option was the most influential factor in the patient's decision-making process. UMIN000000551 (ClinicalTrials.gov).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572140 | PMC |
| http://dx.doi.org/10.1080/14796694.2024.2398985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Neoadjuvant Hypofractionated Chemoradiotherapy in Elderly Patients with Locally Advanced Rectal Cancer: A Single-Center Retrospective Analysis.
Cancers (Basel)
December 2024
Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun 58128, Republic of Korea.
: The application of long-course chemoradiotherapy (LCRT) in elderly patients with locally advanced rectal cancer (LARC) can be challenging due to increased risks of complications associated with comorbidities and reduced functional status. This study aimed to assess the efficacy of neoadjuvant hypofractionated chemoradiotherapy (HCRT) in elderly patients with mid-to-low LARC. : We performed a retrospective review of patients diagnosed with LARC from January 2013 to December 2020 and included those aged 70 years or older.
View Article and Find Full Text PDFCirculating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial).
Cancers (Basel)
December 2024
Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
Background/objectives: Locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). As this approach achieves complete pathologic remissions (pCR) in approximately 30% of patients, it raises the question of whether surgery is always necessary. Non-surgical strategies, such as "watch and wait" (W&W), have shown similarly promising outcomes.
View Article and Find Full Text PDFRectal Cancer: Exploring Predictive Biomarkers Through Molecular Pathways Involved in Carcinogenesis.
Biology (Basel)
December 2024
Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
In 2022, colorectal cancer (CCR) had the second-highest incidence in Europe, preceded only by breast cancer [...
View Article and Find Full Text PDFFDG PET-CT missed tibial metastasis in head and neck cancer, case report and systematic review.
Int J Surg Case Rep
December 2024
Bibliothèque des Sciences de la Santé, Université libre de Bruxelles (ULB), Campus Erasme - CP 607, Route de Lennik, 808, 1070 Bruxelles, Belgium. Electronic address:
Introduction: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common type of cancer in the world. Metastases occur in up to 40 % of cases and bones are the second most frequent site. Metastases in extremities are uncommon with very few publications covering distal lower-limb bone metastasis.
View Article and Find Full Text PDFSafety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study.
Int J Surg
January 2025
Department of Colorectal Surgery.
Objective: To explore the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) combined with a PD-1 antibody in improving complete clinical response (cCR) and organ preservation in patients with ultra-low rectal cancer.
Methods: This was a prospective phase II, single-arm, open-label trial. Patients with confirmed pMMR status T1-3aN0-1M0 retcal adenocarcinoma were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!